Eugene serves as Co-Head of Healthcare Investment Banking and U.S. Head of Biotechnology and Specialty Pharmaceuticals, focused on mergers and acquisitions and capital raising transactions. He joined us in 2010 to enhance our emerging therapeutics sector focus, bringing over 19 years of significant life sciences investment banking experience at HSBC, Wells Fargo, and Robertson Stephens. He has advised clients on a wide variety of corporate finance and strategic assignments, including mergers & acquisitions, IPOs, public offerings and private placements of debt and equity securities, PIPEs and LBOs for both public and private companies. Eugene graduated from the Leonard N. Stern School of Business at New York University with an MBA and a degree in Biology from New York University.
Selected Transactions
-
US$690m
Ascendis Pharma
Co-Lead Manager (Follow-On)
-
US$517m
CRISPR
Co-Manager (Follow-On)
-
US$347m
ChemoCentryx, Inc
Passive Bookrunner (CMPO)
-
US$36m
Kaleido Biosciences, Inc.
Lead Manager (CMPO)
-
US$633m
Allogene Therapeutics, Inc.
Co-Manager (Follow-On)
-
US$202m
Atara Biotherapeutics, Inc.
Co Manager (CMPO)
-
N/a
Histogen, Inc.
Financial Advisor to Histogen, Inc. on its merger with Conatus Pharmaceuticals
-
US$118m
Hutchison China MediTech Limited
Co-Manager (Follow-On)
-
US$325m
Blueprint Medicines Corporation
Co-Lead Manager (Follow-On)